Management of acute attacks of hereditary angioedema: Role of ecallantide

Journal of Blood Medicine

Volumn 6, Issue , 2015, Pages 115-123

  Duffey, Hannah ^a   Firszt, Rafael ^a,b  

^a Department of Pediatrics ^*  (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

7 C1 Inhibitor; ACE Inhibitor induced angioedema; Acquired angioedema; Bradykinin; Idiopathic angioedema; Kallikrein; Nonhistaminergic angioedema

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; ICATIBANT; KALLIKREIN;

ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CLINICAL FEATURE; DIARRHEA; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GENETIC VARIABILITY; HEADACHE; HEALTH CARE COST; HUMAN; INJECTION SITE REACTION; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SCORING SYSTEM; SUFFOCATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 84939120976     PISSN: None     EISSN: 11792736     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Berry A, Firszt R. Successful treatment of idiopathic angioedema with ecallantide. J Allergy Clin Immunol. 2013;1(3):297–298.
2. Zuraw BL. Hereditary angioedema. N Engl J Med. 2008;359(10): 1027–1036.
3. Cicardi M, Agostoni A. Hereditary angioedema. N Engl J Med. 1996; 334(25):1666–1667.
4. Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol. 2009;161(5):1153–1158.
5. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, Lopez-Trascasa M. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol. 2005;94(4):498–503.
6. Psarros F, Koutsostathis N, Farmaki E, Speletas MG, Germenia AE. Hereditary angioedema in Greece: the first results of the Greek hereditary angioedema registry. Int Arch Allergy Immunol. 2014;164(4): 326–332.
7. Aygören-Pürsün E, Bygum A, Beusterien K, et al. Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe. Orphanet J Rare Dis. 2014;9:99.
8. Macginnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R. Use of ecallantide in pediatric hereditary angioedema. Pediatrics. 2013;132(2): e490–e497.
9. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs and course. Am J Med. 2006;119(3):267–274.
10. Jolles S, Williams P, Carne E, et al. A UK national audit of hereditary and acquired angioedema. Clin Exp Immunol. 2013;175(1):59–67.
11. Bork K, Hardt J, Schicketanz K, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med. 2003;163(10): 1229–1235.
12. Sardana N, Craig T. Advances in management and treatment of hereditary angioedema. Pediatrics. 2011;128(6):1173–1180.
13. Zuraw BL, Bork K, Binkley KE, et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 2012;33(Suppl 1):S145.
14. Craig T, Aygören-Pürsün E, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J. 2012;5: 182–199.
15. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343(4):1286–1289.
16. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. Eur J Allergy Clin Immunol. 2007;62(8):842–856.
17. Gompels MM, Lock RJ, Morgan JE, Osborne J, Brown A, Virgo PF. A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. J Clin Pathol. 2002; 55(2):145.
18. Cicardi M, Johston DT. Hereditary and acquired complement component 1 esterase inhibitor deficiency: a review for the Hematologist. Acta Haematol. 2012;127(4):208–220.
19. Kastin AJ, editor. Handbook of Biologically Active Peptides. 2nd ed. Massachusetts: Academic Press; 2013.
20. Bouillet L, Mannic T, Arboleas M, et al. Hereditary angioedema: key role for kallikrein and bradykinin in vascular endothelial-cadherin cleavage and edema formation. J Allergy Clin Immunol. 2011;128(1): 232–234.
21. Frank MM. Update on preventative therapy (prophylaxis) for hereditary angioedema. Immunol Allergy Clin North Am. 2013;33(4):495–503.
22. Zuraw B, Yasothan U, Kirkpatrick P. Ecallantide. Nat Rev Drug Discov. 2010;9(3):189–190.
23. Farkas H, Varga L. Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency. Clin Cosmet Investig Dermatol. 2011;4:61–68.
24. Garnock-Jones KP. Ecallantide in acute hereditary angioedema. Drugs. 2010;70(11):1423–1431.
25. Martello JL, Woytowish MR, Chambers H. Ecallantide for treatment of acute attacks of hereditary angioedema. Am J Health Syst Pharm. 2012;69(8):651–657.
26. US FDA. Center for Drug Evaluation and Research Application 125277: Ecallantide Summary Review of Regulatory Action [online]; 2009. Available from: http://www.accessdata.fda.gov.ezproxy.lib.utah.edu/drugsatfda_docs/nda/2009/125277s000SumR.pdf. Accessed October 16, 2014.
27. Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(6): 523–529.
28. Stolz LE, Sheffer AL. Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema. Expert Rev Clin Immunol. 2012;8(1):25–32.
29. Sheffer AL, MacGinnitie AJ, Campion MC, Stolz LE, Pullman WE. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2013;110(3):184–188.
30. Bernstein JA, Shea EP, Koester J, Iarrobino R, Pullman WE. Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema. Eur J Allergy Clin Immunol. 2012;67(9): 1173–1180.
31. Li HH, Campion M, Craig TJ, et al. Analysis of hereditary angioedema attacks requiring a second dose of ecallantide. Ann Allergy Asthma Immunol. 2013;110(3):168–172.
32. Dy TB, Rasheed M, Parikh P, Bernstein B. Resolution of an acute attack of idiopathic angioedema with ecallantide. Am Allergy Asthma Immunol. 2013;111(3):224–226.
33. Baram M, Kommuri A, Sellers SA, Cohn JR. ACE inhibitor-induced angioedema. J Allergy Clin Immunol. 2013;1(5):442–445.
34. Pare G, Kubo M, Byrd JB, et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2013;23(9):470–478.
35. Cohn JR, McDaniel C, Richards N, Au C, Baram M. Prompt reversal of airway obstruction secondary to angiotensin converting enzyme inhibitor (ACEI) induced angioedema by ecallantide: a case report. J Allergy Clin Immunol. 2012;129(Suppl 2):AB220.
36. Lewis L, Graffeo C, Crosley P, et al. Ecallantide for the acute treatment of angiotensin converting enzyme inhibitor-induced angioedema: a multicenter randomized controlled trial. Ann Emerg Med. 2013;62(Suppl 2):S132.
37. Cicardi M, Zanichelli A. Acquired angioedema. Allergy Asthma Clin Immunol. 2010;6(1):14.
38. Kalbitor® (Ecallantide). The Safety and Efficacy of Ecallantide in Patients with Acquired Angioedema. Cambridge, MA: Dyax Corp; 2014.
39. Patel NS, Fung SM, Zanichelli A, Cicardi M, Cohn JR. Ecallantide for treatment of acute attacks of acquired C1 esterase inhibitor deficiency. Allergy Asthma Proc. 2013;34(1):72–77.
40. Levy R, McNeil D, Li H, et al. Results of a phase 3 double-blind, placebo-controlled trial, EDEMA3: a stubby of subcutaneous DX-88 (ecallantide) in patients with hereditary angioedema [abstract no 15]. J Allergy Clin Immunol. 2008;121(Suppl 2A):A6.
41. KALBITOR® (Ecallantide). Injection, for Subcutaneous Use [Prescribing Information] [online]. Cambridge, MA; Dyax Corp; 2014. Available from: http://www.kalbitor.com/hcp/rems/pdf/KalbitorFullPrescribingInformation.pdf. Accessed October 18, 2014.
42. Craig TJ, Li HH, Riedl M, et al. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2015;3(2):206–212.
43. Kuhlen J, Guyer A, Morphew T, Tachdjian R, Banerji A. Assessment of home infusion program for treating nonlaryngeal hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2014;112(5):471–472.
44. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(4): 314e–320e.
45. Burke S, Petrov A, Johnson J, MacGinnitie A. Successful use of ecallantide to treat a hereditary angioedema attack after failure of C1 inhibitor prophylaxis. Ann Allergy Asthma Immunol. 2011;107(2):181–182.
46. Thomas M, Shah S. New treatment options for acute edema attacks caused by hereditary angioedema. Am J Health Syst Pharm. 2011; 68(22):2129–2138.